UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | K | L | M | O | P | Q | R | S | T | V | W | Y
Number of items: 105.


Al-Qassab, H; Smith, MA; Irvine, EE; Guillermet-Guibert, J; Claret, M; Choudhury, AI; Selman, C; (2009) Dominant Role of the p110 beta Isoform of PI3K over p110 alpha in Energy Homeostasis Regulation by POMC and AgRP Neurons. CELL METAB , 10 (5) 343 - 354. 10.1016/j.cmet.2009.09.008. Gold open access

André, T; Boni, C; Navarro, M; Tabernero, J; Hickish, T; Topham, C; Bonetti, A; (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol , 27 (19) pp. 3109-3116. 10.1200/JCO.2008.20.6771.

Arkenau, H; Evans, J; Lokelma, M; Roxburgh, P; Morisson, R; Coffey, M; Gill, G; (2009) A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. ? - ?). AMER SOC CLINICAL ONCOLOGY

Arkenau, HT; (2009) Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol , 135 (7) pp. 855-866. 10.1007/s00432-009-0583-7.

Arkenau, HT; Barriuso, J; Olmos, D; Ang, JE; de Bono, J; Judson, I; Kaye, S; (2009) Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol , 27 (16) pp. 2692-2696. 10.1200/JCO.2008.19.5081.

Arkenau, HT; Brunetto, AT; Barriuso, J; Olmos, D; Eaton, D; de Bono, J; Judson, I; (2009) Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. Oncology , 76 (3) pp. 151-156. 10.1159/000195884.


Bajwa, A; Blunt, N; Vyas, S; Suliman, I; Bridgewater, J; Hochhauser, D; Ledermann, JA; (2009) Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. EJSO , 35 (2) 164 - 167. 10.1016/j.ejso.2008.06.005.

Berenjeno, IM; Vanhaesebroeck, B; (2009) PI3K regulatory subunits lose control in cancer. Cancer Cell , 16 (6) pp. 449-450. 10.1016/j.ccr.2009.11.017.

Bhosle, J; Makris, A; Hartley, J; Hochhauser, D; (2009) Modulation of topoisomerase II\#945; poison induced DNA damage and repair by tyrosine kinase inhibitiors. CANCER RESEARCH , 69

Billottet, C; Banerjee, L; Vanhaesebroeck, B; Khwaja, A; (2009) Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting Atra-Induced Differentiation. CANCER RES , 69 (3) 1027 - 1036. 10.1158/0008-5472.CAN-08-2608.

Black, E; Glasspool, DW; Grando, MA; Patkar, V; Fox, J; (2009) Goal-Based Decisions for Dynamic Planning. In: Combi, C and Shahar, Y and AbuHanna, A, (eds.) ARTIFICIAL INTELLIGENCE IN MEDICINE, PROCEEDINGS. (pp. 96 - 100). SPRINGER-VERLAG BERLIN

Boone, JJM; Bhosle, J; Tilby, MJ; Hartley, JA; Hochhauser, D; (2009) Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. MOL CANCER THER , 8 (11) 3015 - 3023. 10.1158/1535-7163.MCT-09-0219.

Brown, AC; Hallouane, D; Mawby, WJ; Karet, FE; Saleem, MA; Howie, AJ; Toye, AM; (2009) RhCG is the major putative ammonia transporter expressed in the human kidney, and RhBG is not expressed at detectable levels. Am J Physiol Renal Physiol , 296 (6) F1279-F1290. 10.1152/ajprenal.00013.2009.

Bruce, AW; Lopez-Contreras, AJ; Flicek, P; Down, TA; Dhami, P; Dillon, SC; Koch, CM; (2009) Functional diversity for REST (NRSF) is defined by in vivo binding affinity hierarchies at the DNA sequence level. GENOME RES , 19 (6) 994 - 1005. 10.1101/gr.089086.108.


Cave, J; Edwards, SG; Miller, RF; Ardeshna, KM; Lee, SM; (2009) Should we implement 'opt-out' HIV testing for patients with lymphoma? CLIN MED , 9 (4) 320 - 322.

Chew, SK; Chen, P; Link, N; Galindo, KA; Pogue, K; Abrams, JM; (2009) Genome-wide silencing in Drosophila captures conserved apoptotic effectors. Nature , 460 (7251) pp. 123-127. 10.1038/nature08087.

Chua, YL; Ito, Y; Pole, JCM; Newman, S; Chin, S-F; Stein, RC; Ellis, IO; (2009) The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. ONCOGENE , 28 (46) pp. 4041-4052. 10.1038/onc.2009.259.

Constantinou, A; Epenetos, AA; Hreczuk-Hirst, D; Jain, S; Wright, M; Chester, KA; Deonarain, MP; (2009) Site-Specific Polysialylation of an Antitumor Single-Chain Fv Fragment. BIOCONJUGATE CHEM , 20 (5) 924 - 931. 10.1021/bc8005122.

Cunningham, D; Sirohi, B; Pluzanska, A; Utracka-Hutka, B; Zaluski, J; Glynne-Jones, R; Koralewski, P; (2009) Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol , 20 (2) pp. 244-250. 10.1093/annonc/mdn638.


Dancey, G; Begent, RH; Meyer, T; (2009) Imaging in targeted delivery of therapy to cancer. TARGET ONCOL , 4 (3) 201 - 217. 10.1007/s11523-009-0119-8.

Dancey, G; Violet, J; Malaroda, A; Green, AJ; Sharma, SK; Francis, R; Othman, S; (2009) A Phase I Clinical Trial of CHT-25 a I-131-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. CLIN CANCER RES , 15 (24) 7701 - 7710. 10.1158/1078-0432.CCR-09-1421.

Davis, R; Sielaff, A; Ruprich, J; Westrate, L; Tronrud, C; Ferguson, A; Brown, T; (2009) Design, synthesis, biophysical and biological studies of fluorescent Hoechst-polyamide hybrid molecules. ABSTR PAP AM CHEM S , 237 ? - ?.

Dearling, JLJ; Flynn, AA; Qureshi, U; Whiting, S; Boxer, GM; Green, A; Begent, RHJ; (2009) Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake. NUCL MED BIOL , 36 (8) 883 - 894. 10.1016/j.nucmedbio.2009.07.003.

Desai, K; Bhattacharya, S; Srirajaskanthan, R; Morgan-Rowe, L; Toumpanakis, C; Meyer, T; Caplin, M; (2009) Analysis of association between carcinoid heart disease and mesenteric fibrosis in patients with midgut carcinoid tumour. In: (Proceedings) 45th Annual Meeting of the American-Society-of-Clinical-Oncology. AMER SOC CLINICAL ONCOLOGY

Desai, K; Bhattacharya, S; Srirajaskanthan, R; Morgan-Rowe, L; Toumpanakis, C; Meyer, T; Caplin, M; (2009) Analysis of association between carcinoid heart disease and mesenteric fibrosis in patients with midgut carcinoid tumour. J Clin Oncol , 27 (15_suppl) , Article e15650.

Durand, CA; Hartvigsen, K; Fogelstrand, L; Kim, S; Iritani, S; Vanhaesebroeck, B; Witztum, JL; (2009) Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol , 183 (9) pp. 5673-5684. 10.4049/jimmunol.0900432.


Essafi, A; Gomes, AR; Pomeranz, KM; Zwolinska, AK; Varshochi, R; McGovern, UB; Lam, EW; (2009) Studying the subcellular localization and DNA-binding activity of FoxO transcription factors, downstream effectors of PI3K/Akt. Methods Mol Biol , 462 pp. 201-211. 10.1007/978-1-60327-115-8_13.


Fox, J; Patkar, V; Chronakis, I; Begent, R; (2009) From practice guidelines to clinical decision support: closing the loop. J ROY SOC MED , 102 (11) 464 - 473. 10.1258/jrsm.2009.090010.

Francis, RE; Myatt, SS; Krol, J; Hartman, J; Peck, B; McGovern, UB; Wang, J; (2009) FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol , 35 (1) pp. 57-68.


Giampieri, S; Manning, C; Hooper, S; Jones, L; Hill, CS; Sahai, E; (2009) Localized and reversible TGF beta signalling switches breast cancer cells from cohesive to single cell motility. NAT CELL BIOL , 11 (11) 1287 - U49. 10.1038/ncb1973.

Gibson, F; Aldiss, S; Taylor, RM; Maguire, R; Kearney, N; (2009) Involving health professionals in the development of an advanced symptom management system for young people: The ASyMS (c)-YG study. EUR J ONCOL NURS , 13 (3) 187 - 192. 10.1016/j.ejon.2009.03.004.

Gollmer, K; Asperti-Boursin, F; Tanaka, Y; Okkenhaug, K; Vanhaesebroeck, B; Peterson, JR; Fukui, Y; (2009) CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood , 114 (3) pp. 580-588. 10.1182/blood-2009-01-200923.

Gunaratnam, M; Green, C; Moreira, JB; Moorhouse, AD; Kelland, LR; Moses, JE; Neidle, S; (2009) G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo. Biochem Pharmacol , 78 (2) pp. 115-122.

Gunaratnam, M; Swank, S; Haider, SM; Galesa, K; Reszka, AP; Beltran, M; Cuenca, F; (2009) Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule. J Med Chem , 52 (12) pp. 3774-3783. 10.1021/jm900424a.


Hatton, CSR; Peniket, A; Tusold, A; Collins, GP; Joyner, M; Lee, R; Mouncey, P; (2009) Single arm phase II open label study of thalidomide in patients with refractory or relapsed diffuse large B cell lymphoma. In: (Proceedings) 49th Annual Scientific Meeting of the British-Society-for-Haematology. (pp. p. 13). WILEY-BLACKWELL PUBLISHING, INC

Hochhauser, D; Meyer, T; Spanswick, VJ; Wu, J; Clingen, PH; Loadman, P; Cobb, M; (2009) Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors. CLIN CANCER RES , 15 (6) 2140 - 2147. 10.1158/1078-0432.CCR-08-1315.

Howie, AJ; Brewer, DB; (2009) Optical properties of amyloid stained by Congo red: history and mechanisms. Micron , 40 (3) pp. 285-301. 10.1016/j.micron.2008.10.002.


Kelleher, MT; Fruhwirth, G; Patel, G; Ofo, E; Festy, F; Barber, PR; Ameer-Beg, SM; (2009) The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. Target Oncol , 4 (3) pp. 235-252. 10.1007/s11523-009-0116-y.

Kok, K; Geering, B; Vanhaesebroeck, B; (2009) Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci , 34 (3) pp. 115-127. 10.1016/j.tibs.2009.01.003.

Kok, K; Nock, GE; Verrall, EA; Mitchell, MP; Hommes, DW; Peppelenbosch, MP; Vanhaesebroeck, B; (2009) Regulation of p110δ PI 3-Kinase Gene Expression. PLoS One , 4 (4) , Article e5145. 10.1371/journal.pone.0005145. Green open access

Kristeleit, R; O'Brien, M; (2009) Cardiotoxicity from cytotoxics in the 21st century. British Journal of Cardiology , 16 (2) pp. 60-62.

Kulkarni, AA; Kingsbury, SR; Tudzarova, S; Hong, HK; Loddo, M; Rashid, M; Rodriguez-Acebes, S; (2009) Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma. CLIN CANCER RES , 15 (7) 2417 - 2425. 10.1158/1078-0432.CCR-08-1276.

Kummar, S; Doroshow, JH; Tomaszewski, JE; Calvert, AH; Lobbezoo, M; Giaccone, G; Task Force MDICT, ; (2009) Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies. EUR J CANCER , 45 (5) 741 - 746. 10.1016/j.ejca.2008.10.024.


Lacombe, T; García-Gómez, JJ; de la Cruz, J; Roser, D; Hurt, E; Linder, P; Kressler, D; (2009) Linear ubiquitin fusion to Rps31 and its subsequent cleavage are required for the efficient production and functional integrity of 40S ribosomal subunits. Mol Microbiol , 72 (1) pp. 69-84. 10.1111/j.1365-2958.2009.06622.x.

Lajiness, J; Sielaff, A; MacKay, H; Brown, T; Kluza, J; Nguyen, B; Wilson, WD; (2009) Polyamide Curvature and DNA Sequence Selective Recognition: Use of 4-Aminobenzamide to Adjust Curvature. MED CHEM , 5 (3) 216 - 226.

Larkin, JM; Kipps, EL; Powell, CJ; Swanton, C; (2009) Systemic therapy for advanced renal cell carcinoma. Ther Adv Med Oncol , 1 (1) pp. 15-27. 10.1177/1758834009338430.

Lee, AJ; Kolesnick, R; Swanton, C; (2009) RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance. Expert Rev Mol Med , 11 , Article e15. 10.1017/S1462399409001070.

Lee, SM; James, LE; Qian, W; Spiro, S; Eisen, T; Gower, NH; Ferry, DR; (2009) Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. THORAX , 64 (1) pp. 75-80. 10.1136/thx.2007.093872.

Lee, SM; Woll, PJ; Rudd, R; Ferry, D; O'Brien, M; Middleton, G; Spiro, S; (2009) Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. JOURNAL OF THE NATIONAL CANCER INSTITUTE , 101 (15) pp. 1049-1057. 10.1093/jnci/djp200.

Lee, SM; Woll, PJ; Rudd, R; Ferry, D; O'Brien, M; Middleton, G; Spiro, S; (2009) Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst , 101 (15) pp. 1049-1057. 10.1093/jnci/djp200. Green open access

Liu, D; Zhang, T; Marshall, AJ; Okkenhaug, K; Vanhaesebroeck, B; Uzonna, JE; (2009) The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. J Immunol , 183 (3) pp. 1921-1933. 10.4049/jimmunol.0901099.

Loddo, M; Kingsbur, SR; Rashid, M; Proctor, I; Holt, C; Young, J; El Sheikh, S; (2009) Cell cycle phase progression analysis identifies unique replication phenotypes of major prognostic and predictive significance in cancer. In: CANCER RESEARCH. (pp. 320S - 320S). AMER ASSOC CANCER RESEARCH

Loddo, M; Kingsbury, SR; Rashid, M; Proctor, I; Holt, C; Young, J; El-Sheikh, S; (2009) Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. BRIT J CANCER , 100 (6) 959 - 970. 10.1038/sj.bjc.6604924.

Lowe, HL; Sharma, SK; Bagshawe, KD; Chester, KA; (2009) Antibody directed enzyme prodrug therapy (ADEPT). In: Recombinant Antibodies for Immunotherapy. (pp. 336-349).


Maniaci, V; Davidson, BR; Rolles, K; Dhillon, AP; Hackshaw, A; Begent, RH; Meyer, T; (2009) Fibrolamellar hepatocellular carcinoma - Prolonged survival with multimodality therapy. EJSO-EUR J SURG ONC , 35 (6) 617 - 621. 10.1016/j.ejso.2008.12.009.

Marelli, L; Shusang, V; Buscombe, JR; Cholongitas, E; Stigliano, R; Davies, N; Tibballs, J; (2009) Transarterial Injection of I-131-Lipiodol, Compared with Chemoembolization, in the Treatment of Unresectable Hepatocellular Cancer. JOURNAL OF NUCLEAR MEDICINE , 50 (6) pp. 871-877. 10.2967/jnumed.108.060558.

McCabe, N; Cerone, MA; Ohishi, T; Seimiya, H; Lord, CJ; Ashworth, A; (2009) Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene , 28 (11) pp. 1465-1470. 10.1038/onc.2008.483.

McClelland, SE; Burrell, RA; Swanton, C; (2009) Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle , 8 (20) pp. 3262-3266. 10.4161/cc.8.20.9690.

McGovern, UB; Francis, RE; Peck, B; Guest, SK; Wang, J; Myatt, SS; Krol, J; (2009) Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther , 8 (3) pp. 582-591. 10.1158/1535-7163.MCT-08-0805.

Meyer, T; Gaya, AM; Dancey, G; Stratford, MRL; Othman, S; Sharma, SK; Wellsted, D; (2009) A Phase I Trial of Radioimmunotherapy with I-131-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas. CLIN CANCER RES , 15 (13) 4484 - 4492. 10.1158/1078-0432.CCR-09-0035.

Michelagnoli, M; Kotecha, K; Anazado, A; Flanagan, A; Tirabosco, R; Briggs, T; Cannon, S; (2009) OUTLOOK FOR CHILDREN UNDER 13 YEARS WITH PRIMARY MALIGNANT BONE TUMOURS - THE LONDON SARCOMA SERVICE EXPERIENCE 1999-2009. PEDIATR BLOOD CANCER , 53 (5) 797 - 798.

Morris, JR; Boutell, C; Keppler, M; Densham, R; Weekes, D; Alamshah, A; Butler, L; (2009) The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature , 462 (7275) pp. 886-890. 10.1038/nature08593.

Murugaesu, N; Powles, T; Bestwick, J; Oliver, RT; Shamash, J; (2009) Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis. Osteoporos Int , 20 (9) pp. 1627-1630. 10.1007/s00198-008-0793-x.

Mustapa, MFM; Grosse, SM; Kudsiova, L; Elbs, M; Raiber, EA; Wong, JB; Brain, APR; (2009) Stabilized Integrin-Targeting Ternary LPD (Lipopolyplex) Vectors for Gene Delivery Designed To Disassemble Within the Target Cell. BIOCONJUGATE CHEM , 20 (3) 518 - 532. 10.1021/bc800450r.


O'Donnell, G; Poeschl, R; Zimhony, O; Gunaratnam, M; Moreira, JBC; Neidle, S; Evangelopoulos, D; (2009) Bioactive Pyridine-N-oxide Disulfides from Allium stipitatum. JOURNAL OF NATURAL PRODUCTS , 72 (3) pp. 360-365. 10.1021/np800572r.

Olmos, D; Arkenau, HT; Ang, JE; Ledaki, I; Attard, G; Carden, CP; Reid, AH; (2009) Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol , 20 (1) pp. 27-33. 10.1093/annonc/mdn544.


Panasyuk, G; Nemazanyy, I; Zhyvoloup, A; Filonenko, V; Davies, D; Robson, M; Pedley, RB; (2009) mTOR beta Splicing Isoform Promotes Cell Proliferation and Tumorigenesis. J BIOL CHEM , 284 (45) 30807 - 30814. 10.1074/jbc.M109.056085. Gold open access

Pankhurst, T; Lepenies, J; Nightingale, P; Howie, AJ; Adu, D; Harper, L; (2009) Vasculitic IgA nephropathy: prognosis and outcome. Nephron Clin Pract , 112 (1) c16-c24. 10.1159/000210570.

Patkar, V; Acosta, D; Fox, J; Davidson, T; Keshtgar, M; Jones, A; (2009) A Novel Evidence-Adaptive Computerised Decision Support System for Breast Cancer Multidisciplinary Meetings: Results of an Evaluation Study. In: CANCER RESEARCH. (pp. 805S - 805S). AMER ASSOC CANCER RESEARCH

Plummer, R; Vidal, L; Griffin, M; Lesley, M; de Bono, J; Coulthard, S; Sludden, J; (2009) Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors. CLIN CANCER RES , 15 (9) 3177 - 3183. 10.1158/1078-0432.CCR-08-2859.

Postel-Vinay, S; Arkenau, HT; Olmos, D; Ang, J; Barriuso, J; Ashley, S; Banerji, U; (2009) Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? In: (pp. pp. 1373-1378).


Quinn, AE; Pinkney, M; Piggott, NH; Calvert, H; Milton, ID; Lunec, J; (2009) A Monoclonal Antibody for Detection of Folylpolyglutamate Synthetase in Paraffin Embedded Tissues. HYBRIDOMA , 28 (6) 415 - 421. 10.1089/hyb.2009.0040.


Rahman, KM; Reszka, AP; Gunaratnam, M; Haider, SM; Howard, PW; Fox, KR; Neidle, S; (2009) Biaryl polyamides as a new class of DNA quadruplex-binding ligands. Chem Commun (Camb) (27) 4097 - 4099. 10.1039/b902359c.

Razak, ARA; Nutt, JE; O'Toole, K; Black, F; Plummer, ER; Calvert, AH; Lunec, J; (2009) Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis. Lung Cancer , 63 82 - ?.

Ringland, CL; Arkenau, HT; O'Connell, DL; Ward, RL; (2009) Second primary colorectal cancers (SPCRCs): Experiences from a large Australian cancer registry. Annals of Oncology , 21 (1) pp. 92-97. 10.1093/annonc/mdp288.

Rodríguez-Mateos, M; Abia, D; García-Gómez, JJ; Morreale, A; de la Cruz, J; Santos, C; Remacha, M; (2009) The amino terminal domain from Mrt4 protein can functionally replace the RNA binding domain of the ribosomal P0 protein. Nucleic Acids Res , 37 (11) pp. 3514-3521. 10.1093/nar/gkp209.

Rodríguez-Mateos, M; García-Gómez, JJ; Francisco-Velilla, R; Remacha, M; de la Cruz, J; Ballesta, JP; (2009) Role and dynamics of the ribosomal protein P0 and its related trans-acting factor Mrt4 during ribosome assembly in Saccharomyces cerevisiae. Nucleic Acids Res , 37 (22) pp. 7519-7532. 10.1093/nar/gkp806.


Seymour, LW; Ferry, DR; Kerr, DJ; Rea, D; Whitlock, M; Poyner, R; Boivin, C; (2009) Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. INT J ONCOL , 34 (6) 1629 - 1636. 10.3892/ijo_00000293.

Singh, KJDAL; O'Hare, MJ; Pizzey, A; Appasammy, M; Stein, RC; Muttukrishna, S; (2009) Ovarian Granulosa Cells Have Varying Sensitivity to Different Cytotoxic Drugs Used To Treat Young Breast Cancer Patients. In: (Proceedings) 56th Annual Meeting of the Society-for-Gynecologic-Investigation. (pp. 151A-151A). SAGE PUBLICATIONS INC

Spencer, J; Rathnam, RP; Motukuri, M; Kotha, AK; Richardson, SCW; Hazrati, A; Hartley, JA; (2009) Synthesis of a 1,4-benzodiazepine containing palladacycle with in vitro anticancer and cathepsin B activity. DALTON T (22) 4299 - 4303. 10.1039/b819061e.

Srirajaskanthan, R; Dancey, G; Hackshaw, A; Luong, T; Caplin, ME; Meyer, T; (2009) Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. ENDOCR-RELAT CANCER , 16 (3) 967 - 976. 10.1677/ERC-09-0089.

Srirajaskanthan, R; Desai, K; Jayaratnam, A; Carras, E; Toumpanakis, C; Meyer, T; Caplin, M; (2009) Uncommon sites for metastasis of neuroendocrine tumor in adults. In: (Proceedings) 45th Annual Meeting of the American-Society-of-Clinical-Oncology. AMER SOC CLINICAL ONCOLOGY

Srirajaskanthan, R; Desai, K; Jayaratnam, A; Carras, E; Toumpanakis, C; Meyer, T; Caplin, M; (2009) Uncommon sites for metastasis of neuroendocrine tumor in adults. J Clin Oncol , 27 (15_suppl) , Article e15683.

Srirajaskanthan, R; McStay, M; Toumpanakis, C; Meyer, T; Caplin, ME; (2009) Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review. Neuroendocrinology , 89 (1) pp. 48-55. 10.1159/000151222.

Srirajaskanthan, R; Toumpanakis, C; Karpathakis, A; Marelli, L; Quigley, AM; Dusmet, M; Meyer, T; (2009) Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. Lung Cancer , 65 (1) pp. 68-73. 10.1016/j.lungcan.2008.10.025.

Srirajaskanthan, R; Toumpanakis, C; Meyer, T; Caplin, ME; (2009) Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours. ALIMENTARY PHARMACOLOGY & THERAPEUTICS , 29 (11) pp. 1143-1154. 10.1111/j.1365-2036.2009.03988.x.

Swanton, C; Burrell, RA; (2009) Advances in personalized therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivity. Cancer Biol Ther , 8 (21) pp. 2051-2053.

Swanton, C; Caldas, C; (2009) Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer , 100 (10) pp. 1517-1522. 10.1038/sj.bjc.6605031.

Swanton, C; Nicke, B; Schuett, M; Eklund, AC; Ng, C; Li, Q; Hardcastle, T; (2009) Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A , 106 (21) pp. 8671-8676. 10.1073/pnas.0811835106.


Toumpanakis, C; Quigley, A; Srirajaskanthan, R; Marelli, L; Singhrao, T; Meyer, T; Buscombe, J; (2009) 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors. In: (Proceedings) 45th Annual Meeting of the American-Society-of-Clinical-Oncology. AMER SOC CLINICAL ONCOLOGY

Toumpanakis, C; Quigley, A; Srirajaskanthan, R; Marelli, L; Singhrao, T; Meyer, T; Buscombe, J; (2009) 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors. J Clin Oncol , 27 (15_suppl) 4594-.


Valle, JW; Wasan, H; Johnson, P; Jones, E; Dixon, L; Swindell, R; Baka, S; (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01. British Journal of Cancer , 101 (4) 621 - 627.

Valle, JW; Wasan, H; Johnson, P; Jones, E; Dixon, L; Swindell, R; Baka, S; (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. BRIT J CANCER , 101 (4) 621 - 627. 10.1038/sj.bjc.6605211.

Valle, JW; Wasan, HS; Palmer, DD; Cunningham, D; Anthoney, DA; Maraveyas, A; Hughes, SK; (2009) Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol , 27 (15_suppl) 4503-.

Van Cutsem, E; Rivera, F; Berry, S; Kretzschmar, A; Michael, M; DiBartolomeo, M; Mazier, MA; (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol , 20 (11) pp. 1842-1847. 10.1093/annonc/mdp233.

Vergote, I; Calvert, H; Kania, M; Kaiser, C; Zimmermann, AH; Sehouli, J; (2009) A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. EUR J CANCER , 45 (8) 1415 - 1423. 10.1016/j.ejca.2008.12.013.

Vladimirou, E; Li, M; Aldridge, CP; Frigerio, L; Kirkilionis, M; Robinson, C; (2009) Diffusion of a membrane protein, Tat subunit Hcf106, is highly restricted within the chloroplast thylakoid network. FEBS Lett , 583 (22) pp. 3690-3696. 10.1016/j.febslet.2009.10.057.

von Minckwitz, G; du Bois, A; Schmidt, M; Maass, N; Cufer, T; de Jongh, FE; Maartense, E; (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol , 27 (12) pp. 1999-2006. 10.1200/JCO.2008.19.6618.


Walther, A; Johnstone, E; Swanton, C; Midgley, R; Tomlinson, I; Kerr, D; (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer , 9 (7) pp. 489-499. 10.1038/nrc2645.

Wardley, A; McCaffrey, J; Crown, J; Stein, R; Malik, Z; Rea, D; Barrett-Lee, P; (2009) Preliminary Phase II Data Suggest That Entinostat (SNDX275), a Class 1 Selective Histone Deacetylase Inhibitor (HDACi), May Resensitize Breast Cancer Patients Progressing on Aromataste Inhibitor (AI) Therapy to Their AI Therapy. In: (pp. p. 6111).

Westbury, CB; Reis-Filho, JS; Dexter, T; Mahler-Araujo, B; Fenwick, K; Iravani, M; Grigoriadis, A; (2009) Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ER alpha) in response to therapeutic radiation. J PATHOL , 219 (1) 131 - 140. 10.1002/path.2581.

Westrate, L; Mackay, H; Brown, T; Nguyen, B; Kluza, J; Wilson, WD; Lee, M; (2009) Effects of the N-Terminal Acylamido Group of Imidazole- and Pyrrole-Containing Polyamides on DNA Sequence Specificity and Binding Affinity. BIOCHEMISTRY-US , 48 (24) 5679 - 5688. 10.1021/bi900242t.

Windsor, R; Strauss, S; Seddon, B; Whelan, J; (2009) Experimental therapies in Ewing's sarcoma. EXPERT OPIN INV DRUG , 18 (2) 143 - 159. 10.1517/13543780802715784.

Windsor, R; Strauss, S; Seddon, B; Whelan, J; (2009) Experimental therapies in Ewing’s sarcoma. Expert Opin Investig Drugs , 18 , Article 2.


Yong, M; Tolner, B; Nagl, S; Pedley, RB; Chester, K; Green, AJ; Mayer, A; (2009) Data standards for minimum information collection for antibody therapy experiments. PROTEIN ENG DES SEL , 22 (3) 221 - 224. 10.1093/protein/gzp003.

This list was generated on Sun Feb 26 03:11:53 2017 GMT.